Broken brakes: PRC loss foils menin inhibition.
作者信息
Azimi Nahal, Deshpande Aniruddha J
机构信息
Sanford Burnham Prebys Medical Discovery Institute.
出版信息
Blood. 2024 Nov 7;144(19):1979-1980. doi: 10.1182/blood.2024026297.
Abstract
摘要
相似文献
1
Broken brakes: PRC loss foils menin inhibition.
Blood. 2024 Nov 7;144(19):1979-1980. doi: 10.1182/blood.2024026297.
2
Menin regulates Inhbb expression through an Akt/Ezh2-mediated H3K27 histone modification.
Biochim Biophys Acta Gene Regul Mech. 2017 Apr;1860(4):427-437. doi: 10.1016/j.bbagrm.2017.02.003. Epub 2017 Feb 12.
3
Combined inhibition of KAT6A/B and Menin reverses estrogen receptor-driven gene expression programs in breast cancer.
Cell Rep Med. 2025 Jul 15;6(7):102192. doi: 10.1016/j.xcrm.2025.102192. Epub 2025 Jun 13.
4
Menin regulates the serine biosynthetic pathway in Ewing sarcoma.
J Pathol. 2018 Jul;245(3):324-336. doi: 10.1002/path.5085. Epub 2018 May 28.
5
Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia.
Blood. 2024 Nov 7;144(19):2018-2032. doi: 10.1182/blood.2023023644.
6
EWS-FLI1 and Menin Converge to Regulate ATF4 Activity in Ewing Sarcoma.
Mol Cancer Res. 2021 Jul;19(7):1182-1195. doi: 10.1158/1541-7786.MCR-20-0679. Epub 2021 Mar 19.
7
Targeting Menin disrupts the KMT2A/B and polycomb balance to paradoxically activate bivalent genes.
Nat Cell Biol. 2023 Feb;25(2):258-272. doi: 10.1038/s41556-022-01056-x. Epub 2023 Jan 12.
8
Menin Maintains Cholesterol Content in Colorectal Cancer via Repression of LXR-Mediated Transcription.
Cancers (Basel). 2023 Aug 16;15(16):4126. doi: 10.3390/cancers15164126.
9
p27 Loss Is Associated with Poor Prognosis in Gastroenteropancreatic Neuroendocrine Tumors.
Cancer Res Treat. 2014 Oct;46(4):383-92. doi: 10.4143/crt.2013.102. Epub 2014 Jul 17.
10
Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia.
Exp Hematol. 2019 Jan;69:37-42. doi: 10.1016/j.exphem.2018.10.001. Epub 2018 Oct 10.
引用本文的文献
1
Improved survival with daratumumab-CyBorD compared with CyBorD as frontline therapy for AL amyloidosis.
Blood Neoplasia. 2025 Mar 10;2(2):100092. doi: 10.1016/j.bneo.2025.100092. eCollection 2025 May.
本文引用的文献
1
Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia.
Blood. 2024 Nov 7;144(19):2018-2032. doi: 10.1182/blood.2023023644.
2
Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1.
Blood Cancer J. 2023 Apr 13;13(1):53. doi: 10.1038/s41408-023-00826-6.
3
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia.
Nature. 2023 Mar;615(7954):920-924. doi: 10.1038/s41586-023-05812-3. Epub 2023 Mar 15.
4
MEN1 mutations mediate clinical resistance to menin inhibition.
Nature. 2023 Mar;615(7954):913-919. doi: 10.1038/s41586-023-05755-9. Epub 2023 Mar 15.
5
Targeting Menin disrupts the KMT2A/B and polycomb balance to paradoxically activate bivalent genes.
Nat Cell Biol. 2023 Feb;25(2):258-272. doi: 10.1038/s41556-022-01056-x. Epub 2023 Jan 12.
6
A Molecular Switch between Mammalian MLL Complexes Dictates Response to Menin-MLL Inhibition.
Cancer Discov. 2023 Jan 9;13(1):146-169. doi: 10.1158/2159-8290.CD-22-0416.
7
Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia.
Cancer Discov. 2020 Apr;10(4):536-551. doi: 10.1158/2159-8290.CD-19-0710. Epub 2020 Jan 23.
8
A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia.
Cancer Cell. 2019 Dec 9;36(6):660-673.e11. doi: 10.1016/j.ccell.2019.11.001.
9
MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches.
Front Pediatr. 2017 Feb 9;5:4. doi: 10.3389/fped.2017.00004. eCollection 2017.
10
Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.
Cancer Cell. 2015 Apr 13;27(4):589-602. doi: 10.1016/j.ccell.2015.02.016. Epub 2015 Mar 26.
Zotero 插件